This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA

Principal Results From the Women's Health Initiative Randomized Controlled Trial

Writing Group for the Women's Health Initiative Investigators

JAMA. 2002;288:321-333.

Context  Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain.

Objective  To assess the major health benefits and risks of the most commonly used combined hormone preparation in the United States.

Design  Estrogen plus progestin component of the Women's Health Initiative, a randomized controlled primary prevention trial (planned duration, 8.5 years) in which 16608 postmenopausal women aged 50-79 years with an intact uterus at baseline were recruited by 40 US clinical centers in 1993-1998.

Interventions  Participants received conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n = 8506) or placebo (n = 8102).

Main Outcomes Measures  The primary outcome was coronary heart disease (CHD) (nonfatal myocardial infarction and CHD death), with invasive breast cancer as the primary adverse outcome. A global index summarizing the balance of risks and benefits included the 2 primary outcomes plus stroke, pulmonary embolism (PE), endometrial cancer, colorectal cancer, hip fracture, and death due to other causes.

Results  On May 31, 2002, after a mean of 5.2 years of follow-up, the data and safety monitoring board recommended stopping the trial of estrogen plus progestin vs placebo because the test statistic for invasive breast cancer exceeded the stopping boundary for this adverse effect and the global index statistic supported risks exceeding benefits. This report includes data on the major clinical outcomes through April 30, 2002. Estimated hazard ratios (HRs) (nominal 95% confidence intervals [CIs]) were as follows: CHD, 1.29 (1.02-1.63) with 286 cases; breast cancer, 1.26 (1.00-1.59) with 290 cases; stroke, 1.41 (1.07-1.85) with 212 cases; PE, 2.13 (1.39-3.25) with 101 cases; colorectal cancer, 0.63 (0.43-0.92) with 112 cases; endometrial cancer, 0.83 (0.47-1.47) with 47 cases; hip fracture, 0.66 (0.45-0.98) with 106 cases; and death due to other causes, 0.92 (0.74-1.14) with 331 cases. Corresponding HRs (nominal 95% CIs) for composite outcomes were 1.22 (1.09-1.36) for total cardiovascular disease (arterial and venous disease), 1.03 (0.90-1.17) for total cancer, 0.76 (0.69-0.85) for combined fractures, 0.98 (0.82-1.18) for total mortality, and 1.15 (1.03-1.28) for the global index. Absolute excess risks per 10 000 person-years attributable to estrogen plus progestin were 7 more CHD events, 8 more strokes, 8 more PEs, and 8 more invasive breast cancers, while absolute risk reductions per 10 000 person-years were 6 fewer colorectal cancers and 5 fewer hip fractures. The absolute excess risk of events included in the global index was 19 per 10 000 person-years.

Conclusions  Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women. All-cause mortality was not affected during the trial. The risk-benefit profile found in this trial is not consistent with the requirements for a viable intervention for primary prevention of chronic diseases, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.

Writing Group for the Women's Health Initiative Investigators: Jacques E. Rossouw, MBChB, MD, National Heart, Lung, and Blood Institute, Bethesda, Md; Garnet L. Anderson, PhD, Ross L. Prentice, PhD, Andrea Z. LaCroix, PhD, and Charles Kooperberg, PhD, Fred Hutchinson Cancer Research Center, Seattle, Wash; Marcia L. Stefanick, PhD, Stanford University Clinical Center, Stanford, Calif; Rebecca D. Jackson, MD, Ohio State University Clinical Center, Columbus; Shirley A. A. Beresford, PhD, Fred Hutchinson Cancer Research Center, Seattle, Wash; Barbara V. Howard, PhD, MedStar Research Institute, Washington, DC; Karen C. Johnson, MD, MPH, University of Tennessee, Memphis; Jane Morley Kotchen, MD, Medical College of Wisconsin, Milwaukee; Judith Ockene, PhD, University of Massachusetts Medical School, Worcester.

RELATED LETTER

Hormone Therapy and Cardiovascular Risk
Samuel Shapiro
JAMA. 2007;298(6):623.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Failure of Estrogen Plus Progestin Therapy for Prevention
Suzanne W. Fletcher and Graham A. Colditz
JAMA. 2002;288(3):366-368.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Estrogen Plus Progestin Therapy and Breast Cancer in Recently Postmenopausal Women
Prentice et al.
Am J Epidemiol 2008;167:1207-1216.
ABSTRACT | FULL TEXT  

Article's recommendation of HRT is highly questionable
Lewars
BMJ 2008;336:1033-1034.
FULL TEXT  

Invited Commentary: Postmenopausal Unopposed Estrogen and Breast Cancer Risk in the Women's Health Initiative--Before and Beyond
Linet
Am J Epidemiol 2008;0:kwn089v2-kwn089.
ABSTRACT | FULL TEXT  

Gut, inflammation and osteoporosis: basic and clinical concepts
Tilg et al.
Gut 2008;57:684-694.
ABSTRACT | FULL TEXT  

A Comparison of the Short-Term Effects of Oral Conjugated Equine Estrogens Versus Transdermal Estradiol on C-Reactive Protein, Other Serum Markers of Inflammation, and Other Hepatic Proteins in Naturally Menopausal Women
Shifren et al.
J. Clin. Endocrinol. Metab. 2008;93:1702-1710.
ABSTRACT | FULL TEXT  

Effects in Postmenopausal Women of Estradiol and Medroxyprogesterone Alone and Combined on Resistance Artery Function and Endothelial Morphology and Movement
Kublickiene et al.
J. Clin. Endocrinol. Metab. 2008;93:1874-1883.
ABSTRACT | FULL TEXT  

Vaginal Descent and Pelvic Floor Symptoms in Postmenopausal Women: A Longitudinal Study
Bradley et al.
Obstet Gynecol 2008;111:1148-1153.
ABSTRACT | FULL TEXT  

Docosahexaenoic Acid and 17{beta}-Estradiol Co-Treatment Is More Effective Than 17{beta}-Estradiol Alone in Maintaining Bone Post-Ovariectomy
Poulsen et al.
Exp. Biol. Med. 2008;233:592-602.
ABSTRACT | FULL TEXT  

Estrogen, nitric oxide, and hypertension differentially modulate agonist-induced contractile responses in female transgenic (mRen2)27 hypertensive rats
Brosnihan et al.
Am. J. Physiol. Heart Circ. Physiol. 2008;294:H1995-H2001.
ABSTRACT | FULL TEXT  

Conjugated Equine Estrogens and Breast Cancer Risk in the Women's Health Initiative Clinical Trial and Observational Study
Prentice et al.
Am J Epidemiol 2008;0:kwn090v1-kwn090.
ABSTRACT | FULL TEXT  

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt et al.
BMJ 2008;336:924-926.
FULL TEXT  

FDA Guidance on Off-Label Promotion and the State of the Literature From Sponsors
Psaty and Ray
JAMA 2008;299:1949-1951.
FULL TEXT  

Conjugated Equine Estrogen and Risk of Benign Proliferative Breast Disease: A Randomized Controlled Trial
Rohan et al.
JNCI J Natl Cancer Inst 2008;100:563-571.
ABSTRACT | FULL TEXT  

Re: Breast Cancer Incidence, 1980-2006: Combined Roles of Menopausal Hormone Therapy, Screening Mammography, and Estrogen Receptor Status
Chu
JNCI J Natl Cancer Inst 2008;100:596-597.
FULL TEXT  

Re: Declines in Invasive Breast Cancer and Use of Postmenopausal Hormone Therapy in a Screening Mammography Population
Caan et al.
JNCI J Natl Cancer Inst 2008;100:597-598.
FULL TEXT  

Gender-Related Survival Differences Associated with EGFR Polymorphisms in Metastatic Colon Cancer
Press et al.
Cancer Res. 2008;68:3037-3042.
ABSTRACT | FULL TEXT  

Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts
Horwitz et al.
Proc. Natl. Acad. Sci. USA 2008;105:5774-5779.
ABSTRACT | FULL TEXT  

Increased Risk of Recurrence After Hormone Replacement Therapy in Breast Cancer Survivors
Holmberg et al.
JNCI J Natl Cancer Inst 2008;100:475-482.
ABSTRACT | FULL TEXT  

Should Observational Studies Be a Thing of the Past?
Pritchard
JNCI J Natl Cancer Inst 2008;100:451-452.
FULL TEXT  

Combined HRT increased CV events more than placebo but did not differ from oestrogen HRT after menopause
Cheung
Evid. Based Med. 2008;13:52-52.
FULL TEXT  

Long-term drug prevention trials
Meinert
Clin Trials 2008;5:168-176.
ABSTRACT  

Both low-dose and micro-dose 17{beta}-oestradiol are effective for postmenopausal hot flushes
Dorsen
Evid. Based Nurs. 2008;11:53-53.
FULL TEXT  

Phase III Randomized Placebo-Controlled Trial of Two Doses of Megestrol Acetate as Treatment for Menopausal Symptoms in Women With Breast Cancer: Southwest Oncology Group Study 9626
Goodwin et al.
JCO 2008;26:1650-1656.
ABSTRACT | FULL TEXT  

Discourses on menopause -- Part I: Menopause described in texts addressed to Danish women 1996--2004
Hvas and Gannik
Health (London) 2008;12:157-175.
ABSTRACT  

The Medical Management of Menopause: To Treat or Not To Treat?
BARLOW
Ann. N. Y. Acad. Sci. 2008;1127:134-139.
ABSTRACT | FULL TEXT  

Prediagnostic Use of Hormone Therapy and Mortality After Breast Cancer
Newcomb et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:864-871.
ABSTRACT | FULL TEXT  

Why does menopausal hormone therapy lead to irregular uterine bleeding? Changes to endometrial blood vessels
Hickey et al.
Hum Reprod 2008;23:912-918.
ABSTRACT | FULL TEXT  

Progestogens regulate endothelial actin cytoskeleton and cell movement via the actin-binding protein moesin
Fu et al.
Mol Hum Reprod 2008;14:225-234.
ABSTRACT | FULL TEXT  

The intrinsic resistance of female hearts to an ischemic insult is abrogated in primary cardiac hypertrophy
Bell et al.
Am. J. Physiol. Heart Circ. Physiol. 2008;294:H1514-H1522.
ABSTRACT | FULL TEXT  

Estrogen, medroxyprogesterone acetate, endothelial function, and biomarkers of cardiovascular risk in young women
Meendering et al.
Am. J. Physiol. Heart Circ. Physiol. 2008;294:H1630-H1637.
ABSTRACT | FULL TEXT  

Lipoprotein-Associated Phospholipase A2, Hormone Use, and the Risk of Ischemic Stroke in Postmenopausal Women
Wassertheil-Smoller et al.
Hypertension 2008;51:1115-1122.
ABSTRACT | FULL TEXT  

17{beta}-Estradiol Increases Basal but Not Bradykinin-Stimulated Release of Active t-PA in Young Postmenopausal Women
Pretorius et al.
Hypertension 2008;51:1190-1196.
ABSTRACT | FULL TEXT  

Medroxyprogesterone Abrogates the Inhibitory Effects of Estradiol on Vascular Smooth Muscle Cells by Preventing Estradiol Metabolism
Dubey et al.
Hypertension 2008;51:1197-1202.
ABSTRACT | FULL TEXT  

Wine Polyphenols Improve Endothelial Function in Large Vessels of Female Spontaneously Hypertensive Rats
Lopez-Sepulveda et al.
Hypertension 2008;51:1088-1095.
ABSTRACT | FULL TEXT  

Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections
Krieger
Int J Epidemiol 2008;0:dyn055v1-dyn055.
ABSTRACT | FULL TEXT  

Commentary: Hormone therapy and breast cancer incidence: did epidemiologists miss an effect on national trends?
Paul
Int J Epidemiol 2008;0:dyn058v1-dyn058.
FULL TEXT  

Prevalence of Angina in Women Versus Men: A Systematic Review and Meta-Analysis of International Variations Across 31 Countries
Hemingway et al.
Circulation 2008;117:1526-1536.
ABSTRACT | FULL TEXT  

Psychological and Clinical Factors Implicated in Decision Making About a Trial of Low-Dose Tamoxifen in Hormone Replacement Therapy Users
Rondanina et al.
JCO 2008;26:1537-1543.
ABSTRACT | FULL TEXT  

Oral Contraceptives, Postmenopausal Hormones, and Risk of Asynchronous Bilateral Breast Cancer: The WECARE Study Group
Figueiredo et al.
JCO 2008;26:1411-1418.
ABSTRACT | FULL TEXT  

Risk of New Primary Nonbreast Cancers After Breast Cancer Treatment: A Dutch Population-Based Study
Schaapveld et al.
JCO 2008;26:1239-1246.
ABSTRACT | FULL TEXT  

Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin
Heiss et al.
JAMA 2008;299:1036-1045.
ABSTRACT | FULL TEXT  

Both ovarian hormones estrogen and progesterone are necessary for hormonal mammary carcinogenesis in ovariectomized ACI rats
Blank et al.
Proc. Natl. Acad. Sci. USA 2008;105:3527-3532.
ABSTRACT | FULL TEXT  

Hormone Therapy, Dilemmas, Medical Decisions.
Schulkin
J Law Med Ethics 2008;36:73-88.
 

Cardiovascular disease in women
Stevenson
Menopause Int 2008;14:5-5.
FULL TEXT  

Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer
Powles et al.
Menopause Int 2008;14:6-12.
ABSTRACT | FULL TEXT  

Postmenopausal Hormone Therapy and Lung Cancer Risk in the Cancer Prevention Study II Nutrition Cohort
Rodriguez et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:655-660.
ABSTRACT | FULL TEXT  

Changes in Breast Cancer Incidence Rates
Patani et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:742-742.
FULL TEXT  

Management of Parkinson's disease in older women
Price and Shulman
Menopause Int 2008;14:38-39.
ABSTRACT | FULL TEXT  

Primary prevention of coronary heart disease in women
Rees et al.
Menopause Int 2008;14:40-45.
ABSTRACT | FULL TEXT  

Calcium supplementation and cancer incidence
Bolland and Reid
Am. J. Clin. Nutr. 2008;87:792-793.
FULL TEXT  

Phytoestrogens for Vasomotor Menopausal Symptoms
Obstet Gynecol 2008;111:768-769.
FULL TEXT  

Clinical Pharmacists' Role in Improving Osteoporosis Treatment Rates Among Elderly Patients with Untreated Atraumatic Fractures
Nadrash et al.
The Annals of Pharmacotherapy 2008;42:334-340.
ABSTRACT | FULL TEXT  

Should Urogenital Atrophy in Breast Cancer Survivors Be Treated with Topical Estrogens?
Trinkaus et al.
The Oncologist 2008;13:222-231.
ABSTRACT | FULL TEXT  

Estrogen Plus Progestin and Breast Cancer Detection by Means of Mammography and Breast Biopsy
Chlebowski et al.
Arch Intern Med 2008;168:370-377.
ABSTRACT | FULL TEXT  

Devices for home evaluation of women's health concerns
Scolaro et al.
Am J Health Syst Pharm 2008;65:299-314.
ABSTRACT | FULL TEXT  

ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults
MacLaughlin and Raehl
Am J Health Syst Pharm 2008;65:343-357.
FULL TEXT  

Positive Pressure Therapy: A Perspective on Evidence-based Outcomes and Methods of Application
Sanders et al.
Proc Am Thorac Soc 2008;5:161-172.
ABSTRACT | FULL TEXT  

Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis
MacLean et al.
ANN INTERN MED 2008;148:197-213.
ABSTRACT | FULL TEXT  

Evidence-based common sense?
Sherman
cfp 2008;54:166-168.
FULL TEXT  

Bon sens fonde sur des donnees probantes?
Sherman
cfp 2008;54:169-171.
FULL TEXT  

Differential Regulation of Native Estrogen Receptor-Regulatory Elements by Estradiol, Tamoxifen, and Raloxifene
Levy et al.
Mol. Endocrinol. 2008;22:287-303.
ABSTRACT | FULL TEXT  

Estrogen-Enhanced Gene Expression of Lipoprotein Lipase in Heart Is Antagonized by Progesterone
Liu et al.
Endocrinology 2008;149:711-716.
ABSTRACT | FULL TEXT  

Selective Estrogen Receptor Modulators Accelerate Cutaneous Wound Healing in Ovariectomized Female Mice
Hardman et al.
Endocrinology 2008;149:551-557.
ABSTRACT | FULL TEXT  

Time Since Menopause Influences the Acute and Chronic Effect of Estrogens on Endothelial Function
Vitale et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:348-352.
ABSTRACT | FULL TEXT  

Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Rosamond et al.
Circulation 2008;117:e25-e146.
FULL TEXT  

Is There an Association Between Meningioma and Hormone Replacement Therapy?
Blitshteyn et al.
JCO 2008;26:279-282.
ABSTRACT | FULL TEXT  

Transforming Clinical Practice Guidelines Into Legislative Mandates: Proceed With Abundant Caution
Jacobson
JAMA 2008;299:208-210.
FULL TEXT  

Publication of Clinical Trials in JAMA: Information for Authors
Fontanarosa and DeAngelis
JAMA 2008;299:95-96.
FULL TEXT  

Symptoms Across the Continuum of Acute Coronary Syndromes: Differences Between Women and Men
DeVon et al.
Am J Crit Care 2008;17:14-24.
ABSTRACT | FULL TEXT  

Perimenopausal Depression
Parry
Am. J. Psychiatry 2008;165:23-27.
FULL TEXT  

Relationship between Menopausal Hormone Therapy and Risk of Ductal, Lobular, and Ductal-Lobular Breast Carcinomas
Li et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:43-50.
ABSTRACT | FULL TEXT  

Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era.
Lavie and Milani
J Am Coll Cardiol 2008;51:56-58.
FULL TEXT  

Can Women Be Identified That Will Derive Considerable Cardiovascular Benefits from Postmenopausal Estrogen Therapy?
Clarkson
J. Clin. Endocrinol. Metab. 2008;93:37-39.
FULL TEXT  

Menopause and the virtuous woman: the importance of the moral order in accounting for medical decision making
Stephens and Breheny
Health (London) 2008;12:7-24.
ABSTRACT  

Progressive Diastolic Dysfunction in the Female mRen(2).Lewis Rat: Influence of Salt and Ovarian Hormones
Groban et al.
J. Gerontol. A Biol. Sci. Med. Sci. 2008;63:3-11.
ABSTRACT | FULL TEXT  

Practicing Women's Health with a Simultaneity Worldview in a Medical Model World
Kostas-Polston
Nurs Sci Q 2008;21:32-36.
ABSTRACT  

Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems
Bird and Swain
Clin. Cancer Res. 2008;14:14-24.
ABSTRACT | FULL TEXT  

Selective Estrogen Receptor- Agonists Repress Transcription of Proinflammatory Genes
Cvoro et al.
J. Immunol. 2008;180:630-636.
ABSTRACT | FULL TEXT  

Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation
Corrao et al.
Ann Oncol 2008;19:150-155.
ABSTRACT | FULL TEXT  

Adiposity and Reporting of Vasomotor Symptoms among Midlife Women: The Study of Women's Health Across the Nation
Thurston et al.
Am J Epidemiol 2008;167:78-85.
ABSTRACT | FULL TEXT  

Cardioprotection in female rats subjected to chronic volume overload: synergistic interaction of estrogen and phytoestrogens
Gardner et al.
Am. J. Physiol. Heart Circ. Physiol. 2008;294:H198-H204.
ABSTRACT | FULL TEXT  

Estrogen and Comprehension of Metaphoric Speech in Women Suffering From Schizophrenia: Results of a Double-Blind, Placebo-Controlled Trial
Bergemann et al.
Schizophr Bull 2007;0:sbm138v1-sbm138.
ABSTRACT | FULL TEXT  

Differential Dietary Nutrient Intake according to Hormone Replacement Therapy Use: An Underestimated Confounding Factor in Epidemiologic Studies?
Vercambre et al.
Am J Epidemiol 2007;166:1451-1460.
ABSTRACT | FULL TEXT  

Pharmacogenetic Modulation of Combined Hormone Replacement Therapy by Progesterone-Metabolism Genotypes in Postmenopausal Breast Cancer Risk
Rebbeck et al.
Am J Epidemiol 2007;166:1392-1399.
ABSTRACT | FULL TEXT  

Randomized, Controlled Trial of Acupuncture for the Treatment of Hot Flashes in Breast Cancer Patients
Deng et al.
JCO 2007;25:5584-5590.
ABSTRACT | FULL TEXT  

Why the Slow Diffusion of Treatment Guidelines Into Clinical Practice?
Kotchen
Arch Intern Med 2007;167:2394-2395.
FULL TEXT  

Response: Re: Declines in Invasive Breast Cancer and Use of Postmenopausal Hormone Therapy in a Screening Mammography Population
Kerlikowske et al.
JNCI J Natl Cancer Inst 2007;99:1816-1817.
FULL TEXT  

Re: Declines in Invasive Breast Cancer and Use of Postmenopausal Hormone Therapy in a Screening Mammography Population
Anderson
JNCI J Natl Cancer Inst 2007;99:1815-1816.
FULL TEXT